Zura Bio Limited (NASDAQ: ZURA)’s stock price has dropped by -11.92 in relation to previous closing price of 6.88. Nevertheless, the company has seen a loss of -1.30% in its stock price over the last five trading days. The Motley Fool reported 2023-06-20 that Zura Bio’s lead therapy is ZB-106. The company plans to start two phase 2 trials for the therapy.
Is It Worth Investing in Zura Bio Limited (NASDAQ: ZURA) Right Now?
, and the 36-month beta value for ZURA is at 0.44. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
The average price suggested by analysts for ZURA is $18.25, which is $12.19 above the current market price. The public float for ZURA is 19.80M, and currently, shorts hold a 0.80% of that float. The average trading volume for ZURA on September 18, 2023 was 221.13K shares.
ZURA’s Market Performance
The stock of Zura Bio Limited (ZURA) has seen a -1.30% decrease in the past week, with a -12.68% drop in the past month, and a -25.37% fall in the past quarter. The volatility ratio for the week is 8.28%, and the volatility levels for the past 30 days are at 6.38% for ZURA. The simple moving average for the past 20 days is -11.01% for ZURA’s stock, with a -33.12% simple moving average for the past 200 days.
Analysts’ Opinion of ZURA
Many brokerage firms have already submitted their reports for ZURA stocks, with Oppenheimer repeating the rating for ZURA by listing it as a “Outperform.” The predicted price for ZURA in the upcoming period, according to Oppenheimer is $17 based on the research report published on August 25, 2023 of the current year 2023.
ZURA Trading at -9.81% from the 50-Day Moving Average
After a stumble in the market that brought ZURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.86% of loss for the given period.
Volatility was left at 6.38%, however, over the last 30 days, the volatility rate increased by 8.28%, as shares sank -10.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.65% lower at present.
During the last 5 trading sessions, ZURA fell by -1.30%, which changed the moving average for the period of 200-days by -39.34% in comparison to the 20-day moving average, which settled at $6.78. In addition, Zura Bio Limited saw -40.65% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZURA starting from Munshi Amit, who purchase 117,647 shares at the price of $4.25 back on Jun 05. After this action, Munshi Amit now owns 617,640 shares of Zura Bio Limited, valued at $500,000 using the latest closing price.
Stock Fundamentals for ZURA
The total capital return value is set at -2.02, while invested capital returns managed to touch 2.69. Equity return is now at value -58.90, with -48.70 for asset returns.
Based on Zura Bio Limited (ZURA), the company’s capital structure generated 0.27 points at debt to equity in total, while total debt to capital is 0.27.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.02.
Conclusion
In conclusion, Zura Bio Limited (ZURA) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
